Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.310 -0.220 (-2.31%)
Streaming Delayed Price Updated: 10:36 AM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
5 Analysts Have This to Say About Evolus
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
Via Benzinga
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
Via Investor Brand Network
Why Shares of Evolus Are Jumping Thursday
The stock climbed on record second-quarter revenue and a raise in full-year guidance. 
Via The Motley Fool
Comcast, STMicroelectronics, Lam Research, Meta Platforms And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Expert Ratings for Evolus
 
Via Benzinga
This Analyst Likes Evolus As 'Top Play In Aesthetics'
Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S. 
Via Benzinga
Expert Ratings for Evolus
 
Via Benzinga
Evolus: Q1 Earnings Insights
 
Via Benzinga
Evolus Earnings Preview
 
Via Benzinga
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
From Evolus, Inc.
Via Business Wire
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Twitter Faces Threats From AI and Threads
AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience. 
Via The Motley Fool
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Analyst Expectations for Evolus's Future
 
Via Benzinga
Preview: Evolus's Earnings
 
Via Benzinga
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
From Evolus, Inc.
Via Business Wire
Evolus to Report First Quarter 2023 Results and Provide Business Update
From Evolus, Inc.
Via Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
From Evolus, Inc.
Via Business Wire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.